Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

NPS Pharmaceuticals Reports NatparaTM Phase 3 Results to be Presented at ENDO, the annual meeting of The Endocrine Society

Eddie Staley, Benzinga Staff Writer
June 18, 2012 4:10 PM
+ Follow
Print
Email
Tickers: NPSP
Benzinga Share:

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported that three abstracts related to the Phase 3 REPLACE study of Natpara™ in hypoparathyroidism will be presented at ENDO 2012, the annual meeting of The Endocrine Society in Houston, TX, June 23-26, 2012.

(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Posted in: News, FDA, Events

 

Around the Web, We're Loving...

Obama Taking Action on Gun Background Check System
One Boston Suspect Dead, Police Search For Second
Can Netflix Be a Blockbuster Again? Click here to access an exclusive research report on NFLX from The Motley Fool

Most Popular

America's Top VCs Think These 54 Companies Are the Next Big Thing
Legendary VC Paul Graham Suspects Bitcoin Was Created by a Government
Weekly Preview: Earnings Season Continues, Apple In Focus
Netflix Earnings Preview: Another Profitable Quarter Expected
Google Drive Outage Shows Why the Cloud Can't Replace Everything
These 11 Companies Are Teaming Up to Help Victims of the Boston Marathon Bombings

Related Articles (NPSP)

UPDATE: Wedbush Raises PT on NPS Pharmaceuticals on Rights Buyback
UPDATE: Jefferies Raises PT on NPS Pharmaceuticals on Regained Product Rights
Market Wrap for Tuesday, March 19: Dow Records Slight Gain, Nasdaq and S&P Close Lower
Mid-Afternoon Market Update: Copper Continues to Take a Beating, Lattice Semiconductor Rallies
Mid-Day Market Update: Markets Turn Red, DSW Declines On Downbeat View
Benzinga's Volume Movers

Partner Network

Get Benzinga's News Delivered Free

Posts by Eddie Staley

Benzinga Professional

Subscribe